BioLife Solutions (BLFS)
(Delayed Data from NSDQ)
$22.88 USD
+0.79 (3.58%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $22.87 -0.01 (-0.04%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
BLFS 22.88 +0.79(3.58%)
Will BLFS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BLFS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BLFS
Owens & Minor (OMI) Q2 Earnings and Revenues Surpass Estimates
ResMed (RMD) Beats Q4 Earnings and Revenue Estimates
BLFS: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes BioLife Solutions (BLFS) a Good Fit for 'Trend Investing'
BioLife (BLFS) Progresses in Cell & Gene Therapy With CryoCase
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates
Other News for BLFS
Analysts Conflicted on These Healthcare Names: BioLife Solutions (BLFS), Arvinas Holding Company (ARVN) and Natera (NTRA)
BioLife Solutions to Report Second Quarter 2024 Financial Results and Business Update on August 8, 2024
BioLife Solutions price target raised by $6 at TD Cowen, here's why
BioLife Solutions: Strong Buy Rating on Robust Gross Margins and Positive Long-Term EBITDA Outlook
Insider Sale: Todd Berard Sells 10,000 Shares of BioLife Solutions Inc (BLFS)